Equities analysts expect Moderna, Inc. (NASDAQ:MRNA) to report earnings of $6.35 per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Moderna’s earnings, with estimates ranging from $3.27 to $8.23. Moderna posted earnings of ($0.31) per share during the same quarter last year, which would indicate a positive year over year growth rate of 2,148.4%. The business is scheduled to report its next earnings report on Wednesday, August 4th.
Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Moderna.
Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 6th. The company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.80. The company had revenue of $1.94 billion during the quarter, compared to analyst estimates of $2.48 billion. Moderna had a return on equity of 19.76% and a net margin of 21.90%. Moderna’s quarterly revenue was up 24112.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.35) earnings per share.
In related news, insider Tal Zvi Zaks sold 1,199 shares of the stock in a transaction on Monday, March 22nd. The stock was sold at an average price of $144.82, for a total value of $173,639.18. Following the sale, the insider now owns 1,199 shares in the company, valued at $173,639.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Stephen Hoge sold 15,000 shares of the stock in a transaction on Monday, March 15th. The stock was sold at an average price of $137.00, for a total value of $2,055,000.00. Following the completion of the sale, the president now owns 1,614,597 shares in the company, valued at approximately $221,199,789. The disclosure for this sale can be found here. Insiders sold 2,132,589 shares of company stock worth $280,419,650 in the last quarter. 19.40% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gerber Kawasaki Wealth & Investment Management raised its position in Moderna by 0.9% during the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 7,420 shares of the company’s stock valued at $775,000 after purchasing an additional 65 shares in the last quarter. Carl P. Sherr & Co. LLC raised its position in Moderna by 1.4% during the fourth quarter. Carl P. Sherr & Co. LLC now owns 5,227 shares of the company’s stock valued at $546,000 after purchasing an additional 74 shares in the last quarter. Duncker Streett & Co. Inc. raised its position in Moderna by 14.4% during the first quarter. Duncker Streett & Co. Inc. now owns 595 shares of the company’s stock valued at $78,000 after purchasing an additional 75 shares in the last quarter. Allworth Financial LP raised its position in Moderna by 5.4% during the first quarter. Allworth Financial LP now owns 1,667 shares of the company’s stock valued at $218,000 after purchasing an additional 85 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd raised its position in Moderna by 3.2% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 2,876 shares of the company’s stock valued at $300,000 after purchasing an additional 90 shares in the last quarter. Institutional investors and hedge funds own 51.67% of the company’s stock.
NASDAQ MRNA traded down $2.56 on Friday, hitting $214.44. 115,621 shares of the stock traded hands, compared to its average volume of 11,188,439. The stock’s fifty day simple moving average is $168.85. Moderna has a 12 month low of $54.21 and a 12 month high of $227.71. The company has a market cap of $86.10 billion, a price-to-earnings ratio of 173.60, a price-to-earnings-growth ratio of 0.76 and a beta of 1.48. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.39 and a quick ratio of 1.33.
Moderna Company Profile
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.
Recommended Story: Retained Earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.